Biocon, Asia’s premier biotechnology company, has signed an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), which will make a primary equity investment in its research services subsidiary, Syngene International (Syngene). The Biocon Group was advised by Allegro Corporate Finance Advisors and Mundkur Law Partners.
As per the terms of the agreement, GE Capital would invest Rs 125 crore for a 7.69% equity share in Syngene. However, the transaction is subject to standard condition precedents including regulatory approvals.
Syngene registered nearly Rs 400 crore in FY12. During H1, FY13, the business continues to gain momentum with sales of nearly Rs 250 crore.
Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.00 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: